Literature DB >> 3666278

Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation.

J A Fontana1.   

Abstract

The growth of chemically induced mammary tumors is inhibited by both hormone manipulation as well as by retinoids. Numerous mammary carcinoma cell lines are also inhibited by retinoids. Co-treatment of estrogen receptor (ER)-positive breast cancer cells resulted in an additive effect in terms of inhibition of cellular proliferation. The addition of varying concentrations of retinoic acid (RA) to varying concentrations of tamoxifen (TMX) resulted in an additive effect on the inhibition of proliferation of the ER-positive human carcinoma cell lines (MCF-7). Co-treatment of MCF-7 cells over time with RA and TMX resulted in enhanced inhibition of growth. A similar phenomenon was observed when other synthetic retinoids were combined with TMX. This enhanced inhibition by the combination of retinoids and TMX was also observed with other ER-positive cell lines (ZR-75, T47-D), while no effect was noted on the ER-negative cell lines (MDA-MB-231, Hs578T).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3666278     DOI: 10.1159/000163409

Source DB:  PubMed          Journal:  Exp Cell Biol        ISSN: 0304-3568


  18 in total

1.  Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids.

Authors:  Q Wu; M I Dawson; Y Zheng; P D Hobbs; A Agadir; L Jong; Y Li; R Liu; B Lin; X K Zhang
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

2.  Synergistic transcriptional activation of the mouse urokinase plasminogen activator (uPA) gene and of its enhancer activator protein 1 (AP1) site by cAMP and retinoic acid.

Authors:  R Mira-Y-Lopez; S Jaramillo; Y Jing
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

3.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells.

Authors:  Y Liu; M O Lee; H G Wang; Y Li; Y Hashimoto; M Klaus; J C Reed; X Zhang
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Authors:  F Boccardo; L Canobbio; M Resasco; A U Decensi; G Pastorino; F Brema
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor beta.

Authors:  R K Srivastava; A R Srivastave; Y S Cho-Chung
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

Review 6.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha.

Authors:  Krishanu Sengupta; Snigdha Banerjee; Neela K Saxena; Nira Ben Jonathan; Donald R Campbell; Sushanta K Banerjee
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

8.  Polyprenoic acid, E-5166, is effective in inhibiting the proliferation of keratinocytes in vitro.

Authors:  M Koji; T Kanzaki; A Takashima
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 9.  The efficacy of 9-cis retinoic acid in experimental models of cancer.

Authors:  M M Gottardis; W W Lamph; D R Shalinsky; A Wellstein; R A Heyman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

Authors:  E Elstner; C Müller; K Koshizuka; E A Williamson; D Park; H Asou; P Shintaku; J W Said; D Heber; H P Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.